William L. Herring

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter by Year

Filter by Publication Type

Search Results

IPECAD modeling workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease

New international pharmaco-economic collaboration on Alzheimer's disease (IPECAD) open-source model framework for the health technology assessment of early Alzheimer's disease treatment: Development and use cases

Cost-effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States

Value assessment of emerging treatments for nonalcoholic steatohepatitis: Lessons from institute for clinical and economic review evaluations

A targeted literature review of lung function decline in idiopathic pulmonary fibrosis to improve survival predictions in cost-effectiveness analyses

People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare

Evaluating elements of the care partner experience in individuals who care for people with Alzheimer's disease across the severity spectrum

Going forward: Potential impact of protein-based COVID-19 vaccination coverage on population outcomes and costs in the United States

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

Use of patient-reported outcomes as key drivers in cost-effectiveness models: A review of UK National Institute for Health and Care excellence Health Technology assessments

Relationships among sickle cell disease complications and their implications for Cost-Effectiveness modeling for therapies with Curative intent

Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

Cost-effectiveness of respiratory syncytial virus preventive interventions in children: A model comparison study

Evaluation of emerging NASH therapies: The impact of treatment efficacy profiles on long-term health outcomes

Assessing the cost-effectiveness of the novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States

Cost-effectiveness of respiratory syncytial virus (RSV) prevention interventions in children: A model comparison study

The relationship between asthma control questionnaire scores and exacerbation risk, resource utilization, and utility values: An analysis from the captain trial

What might have happened: The impact of interrupting entry of innovative drugs on disease outcomes in the United States

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom

Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States